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Abstract
BACKGROUND: Uterine fibroids (UFs) affect women of reproductive age and lead to major morbidity in 
premenopausal women. Identifying modifiable risk factors could help develop new UF prevention and treatment 
strategies.
OBJECTIVES: The purpose of this research was to investigate the relationship between serum Vitamin D3 levels 
and UF in women seeking gynecological services.
METHODS: This case–control design was conducted in September 2018 at the outpatient gynecology clinic of 
Shahid Beheshti University of Medical Sciences, Tehran, Iran. Cases had at least one ultrasound confirmed fibroid 
lesion with an average volume of 2 cm or greater. The outpatient clinic has enrolled a control group of patients without 
UF, based on transvaginal ultrasonography or any other gynecologic pathology. Radioimmunoassay techniques 
were applied to measure serum Vitamin D [25(OH) D3] levels.
RESULTS: A total of 148 patients met inclusion criteria, 71 women were had at least one UF and the remaining 77 
participants showed normal, UF-free uterine structure. The mean serum concentration of 25-hydroxyvitamin D3 was 
lower in UF patients (21.37 ± 7.49 ng/mL) than without (24.62 ± 9.21 ng/mL) (p = 0.02). A modified odds ratio derived 
from a backward logistic regression model for 25-hydroxyvitamin D3 that included positive family history, age, body 
mass index, bleeding volume, physical activity, sun exposure, and history of abortion was 0.92 (95% CI, 0.88–0.98) 
(P = 0.02).
CONCLUSION: For women with UFs, the serum level of 25-hydroxyvitamin D3 was significantly lower than in 
controls. Vitamin D3 deficiency is a potential risk factor for UFs to occur.
Introduction
One of the most common pathologies in 
women of reproductive age is uterine leiomyomas 
(fibroids), a benign neoplasm of uterine smooth muscle 
cells [1]. Based on clinical diagnosis or diagnostic tests 
reports, the incidence of premenopausal women varies 
from 30% to 70% and rises with increasing age [2].
Uterine fibroids (UFs) lead to major morbidity 
in premenopausal women, regardless of their 
inherently benign neoplastic character [3]. Several 
studies have shown that fibroids have negative effects 
on iron deficiency anemia, stomach disorders, female 
pregnancy, and obstetric complications such as 
miscarriage and preterm labor [4], [5], [6].
Although the etiology of fibroids is unknown, 
there have been a sizeable scientific literature 
pertaining to the main factor inducing age, parity, race, 
obesity, family history, and serum micronutrients [7]. 
Over the past decade, it has been hypothesized whether 
Vitamin D deficiency is associated with fibroid. In 
2008, Baird et al. demonstrated that women with 
Vitamin D insufficiency have a higher chance of 
developing UFs compared to women with normal 
levels of Vitamin D. Furthermore, the prevalence of 
UFs was significantly higher in Blacks rather Whites 
(75% vs. 51%; p < 0.001). As a result, more skin 
pigmentation tends to be correlated with lower Vitamin 
D status and higher UFs prevalence [8]. Although 
this association was seen in several studies, it has 
not been repeated in different populations, and 
the results are still contradictory [9], [10], [11], [12]. 
Multiple population-based studies have been carried 
out about the prevalence of Vitamin D deficiency in 
Iran [13], [14], [15], [16]. The meta-analysis of 48 
studies including 18, 531 participants estimated the 
high prevalence of Vitamin D deficiency among male 
(45.64%, 95% CI: 29.63–61.65), female (61.90%, 95% 
CI: 48.85–74.96), and pregnant women (60.45%, 95% 
CI: 23.73–97.16) [17]. Along with the high prevalence of 
Vitamin D deficiency, a high prevalence of reproductive 
morbidity and health-seeking activity among women of 
reproductive age in Iran has been identified [18]. This 
study, therefore, was aimed to explore the relationship 
between serum Vitamin D3 levels and UFs in Iranian 
women seeking gynecological services.
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Methods
This case–control study was conducted in 
September 2018 at the Shahid Beheshti University of 
Medical Sciences, Tehran, Iran’s outpatient gynecology 
clinic. There was no treatment or intervention involved in 
this study, and this study was approved by the Medical 
School Ethical Committee.
Subjects
Case subjects in the present study were 
recruited among the women referred to Emam Hossein 
Hospital, for surgical removal of the UF or hysterectomy, 
and had at least one lesion with an average volume of 
2 cm or more that was detected with transvaginal or 
abdominal ultrasound scan. Total uterine volume and 
total volume of fibroid were measured for each subject. 
Using a General Electric Voluson E8 BT 13 with 
transvaginal I-C 5-9 D probe and abdominal RAB 4-8 
D probe, the ultrasound examination was performed 
by a gynecologist qualified for genital tract sonography. 
In the case of large fibroids, the area of the pelvis 
minor and the abdominal area (including the uterus 
and the adnexa) were investigated. UF is defined as a 
symmetrical area with distinct margins, hypoechogenic, 
and heterogeneous.
The outpatient clinic has enrolled a control 
group of patients without UF, based on transvaginal 
ultrasonography (TVU) or any other gynecologic 
pathology. Control patients were asked for consent 
during their visits to the clinic to take part in the study 
(for cervical smears, control ultrasounds, etc.). Eligible 
candidates obtained written informed consent before 
participation in the study.
Women were not eligible to participate in 
this study if they had: (1) Previous myomectomy or 
hysterectomy; (2) active pregnancy or pregnancy within 
6 months of study commencement, (3) currently lactating 
or lactating within 6 months before the beginning of 
the study, (4) candidates who have had an abortion or 
miscarriage within 6 months of the start of the study, and 
(5) diabetes(6) used a vitamin supplement or hormonal 
therapy during or within 6 months of enrolment.
Blood assay
During the study visit, blood samples 
(about 12 mL) were also obtained from each 
participant. Radioimmunoassay techniques 
described previously [19], [20], [21] were applied 
to measure serum Vitamin D3 [25(OH) D3] levels. 
25(OH) D3 was assessed using a direct, competitive 
chemiluminescence immunoassay at Heartland 
Assays, Inc. (Ames, IA) with DiaSorin Liaison 25(OH) 
D3 Total Testing platform [20], [21]. The sensitivity for 
this assay is 2.5 ng/mL, and the coefficients of variation 
between intra-assay are 11.2% and 8.1%, respectively. 
Endogenous 25(OH) D recovery is 100% [19]. Vitamin 
D3 was categorized based on the definition of Ritu 
and Gupta, so that, Vitamin D deficiency is defined as 
25(OH) D <20 ng/mL, insufficiency as 20–29 ng/mL, 
and sufficiency as ≥30 ng/mL [22].
Physical activity was categorized according 
to metabolic equivalents (METs) questionnaire. The 
thresholds were defined as light, <3.0 METs; moderate, 
3.0–5.9 METs; and vigorous ≥6.0 METs [23]. In addition, 
we categorized sun exposure according to self-
administered short-term SEM-Q questionnaire [24]. The 
questionnaire asks about time (min) spent outdoors, 
weather, clothing, use of sunscreen, sun protection 
practices, use of multivitamin, and skin tone.
Statistical analysis
Data were presented as mean, standard 
deviation (SD), and percentage. For qualitative 
characteristics, the Chi-square independence test 
was used to determine the differences between the 
groups. The independent t-test was used to compare 
serum Vitamin D levels and quantitative variables 
between the two study groups. A backward logistic 
regression model was applied to select the variables 
for measuring the association between serum levels 
of Vitamin D and UF adjusting for variables known 
to be associated with UF. p < 0.05 was considered 
statistically significant. Data analysis was carried out 
by statistical software (SPSS, v 24; IBM Corporation, 
Armonk, NY, USA).
Sample size
The sample size was determined using an 
estimated 25-hydroxyvitamin D3 concentration in 20.4 
controls (SD = 11.8 ng/mL) [25] and stating as clinically 
relevant 30% lower concentration in women with 
leiomyomas. Type I and II errors were set at 0.05 and 
0.20, respectively, roughly 71 cases and 77 controls are 
calculated for women to be recruited.
Results
A total 148 patients met inclusion criteria and 
were included in the study. TVU confirmed that 71 of 
these participants had at least one UF (with a volume of 
2 cm3 or greater) (Table 1). The remaining 77 participants 
displayed no UFs of normal uterine structure.
The age of participants ranged from 16 to 
77 years (mean age, 41.15 ± 10.98 years). The mean 
age of the women with fibroids (42.71 ± 8.07 years) 
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was slightly higher than the normal subjects, but not 
significantly different (39.75 ± 12.95 years; p = 0.10). 
In contrast, the fibroid group’s mean body mass 
index (BMI) (28.24 ± 5.41) was higher than that of 
the control subjects, but it was not significant (26.96 ± 
4.61; p = 0.13).
The number of women with 1, 2, and 3 or 
more fibroids was 89 (60.14%), 22 (14.86%), and 
37 (25%), respectively. Overall, women had 238 
lesions; 96 (65%) intramural, 37 (25%) subserosal, 
and 15 (10%) submucosa. The mean diameter of the 
fibroids was 21 mm (SD = 14), and the mean diameter 
of the larger lesion per woman was 24 mm (SD = 15). 
Table 1 displays the baseline characteristics of the two 
study groups.
The analysis demonstrated that the serum 
levels of 25-hydroxyvitamin D3 significantly differed 
in both groups (p = 0.02). The mean serum levels of 
25-hydroxyvitamin D3 were 21.37 ± 7.49 ng/mL and 
24.62 ± 9.21 ng/mL, respectively, in patients with 
and without UF. Furthermore, Vitamin D3 deficiency 
was more prevalent for women with UF than control 
group, and the difference was statistically significant 
(p = 0.003).
A modified odds ratio (OR) derived 
from a backward logistic regression model for 
25-hydroxyvitamin D3 that included positive family 
history, age, BMI, bleeding volume, physical activity, 
sun exposure, and history of abortion was 0.92 (95% 
CI, 0.88–0.98) (p = 0.02). Patients with a positive 
family history had a triple higher risk of developing UF 
(OR = 2.85, 95% CI, 1.16–6.99) compared to women 
with a negative family background. A one unit rise in 
BMI increased the chances of UF by 1.15 (OR = 1.15; 
95% CI, 1.02–1.39). An increase in bleeding volume 
increases the risk for UF by 2.08 (OR = 2.08; 95% CI, 
1.73–5.88). Table 2 reported the results of the logistic 
regression model.
Discussion
To the best of our knowledge, this is a first 
study to evaluate the association of Vitamin D3 status 
of Iranian women with UFs. The results of the current 
study showed that the serum level of 25-hydroxyvitamin 
D3 was significantly lower in women with UFs compared 
to controls. This association was also significant after 
adjusting for confounding variables, including family 
history of fibroids, BMI, and menstrual bleeding.
The results of our study are in line with those in 
different geographic regions and with different cultural 
contexts. Baird et al. conducted a prospective cohort 
study within a large health plan in Washington, DC 
between 1996 and 1999. Briefly, 1036 premenopausal 
women were screened for fibroids with transvaginal and 
transabdominal ultrasound. It was found that women with 
adequate 25(OH) D3 circulation (>20 ng/ml) had lower 
levels of fibroids compared to those with insufficient 
Vitamin D3 (adjusted OR = 0.68, 95% CI: of 0.48, 0.96), 
and there was no evidence of heterogeneity between 
Black and White women. Furthermore, the prevalence 
of UFs was significantly higher in Blacks rather Whites 
(75% vs. 51%; p < 0.001). Hence, they conclude that 
more skin pigmentation tends to be correlated with 
lower Vitamin D status and higher UFs prevalence [8]. In 
another cross-sectional study by Sabry et al., circulating 
25 (OH) D3 levels of 104 women who had at least one 
fibroid lesion compared to 50 women with a normal, 
fibroid-free uterine structure. They found an inverse 
association in all ethnic groups between 25(OH) D3 
deficiency (measured by radioimmunoassay) and the 
occurrence of uterine leiomyomas [9].
There are also a few studies that have not 
seen the association between Vitamin D and uterine 
leiomyomas. In a large cross-sectional study conducted 
between 2001 and 2006, there was no association 
between serum levels of 25(OH) D and self-reported 
UL diagnosis among 3590 premenopausal women. The 
authors acknowledged that the case finding method 
would result in differential misclassification resulting in 
an “underestimation” of the hypothesized association 
between 25(OH) D3 deficiency and uterine leiomyomas 
occurrence [12].
Although there is no clinical trial to evaluate 
the effect of Vitamin D on fibroids, it has been proven 
in several in vitro studies. Blauer et al. found that 
Table 1: Baseline characteristics of women with and without 
uterine fibroids
Characteristics Uterine fibroids 
(n=71)
Control (n=77) p-value
Age, year 42.71 ± 8.07 39.75 ± 12.95 0.010
BMI, kg/m2 28.24 ± 5.41 26.96 ± 4.61 0.13
Age at first menstruation, year 13.09 ± 1.19 12.89 ± 1.20 0.33
Age at first delivery, year 23.86 ± 19.34 21.77 ± 5.26 0.45
Family history, yes (%) 18 (25.35) 12 (15.59) 0.07
Bleeding volume
Low (%) 5 (7.04) 13 (16.88)
Moderate (%) 33 (46.48) 49 (63.64)
High (%) 33 (46.48) 15 (19.48) 0.001
History of infertility, yes (%) 10 (14.08) 6 (7.79) 0.22
History of abortion, yes (%) 24 (33.80) 17 (22.08) 0.09
Sun exposure
Low (%) 32 35
Moderate (%) 34 29
High (%) 5 13 0.09
Physical activity
Low (%) 18 (25.35) 17 (22.08)
Moderate (%) 35 (49.30) 44 (57.14)
High (%) 18 (25.35) 16 (20.78) 0.64
History of myometrial, yes (%) 33 (46.4) 10 (13) <0.0001
Serum level 25-hydroxyvitamin D3, ng/ml 21.37 ± 7.49 24.62 ± 9.21 0.02
Deficiency (%) 30 (42.25) 17 (22.08)
Insufficiency (%) 23 (32.40) 20 (25.97)
Sufficiency (%) 18 (25.35) 40 (51.95) 0.003
BMI: Body mass index.
Table 2: Logistic regression model for uterine fibroids
Variable Odds ratio (95% CI) p-value
Serum level 25-hydroxyvitamin D3, ng/ml 0.92 (0.88–0.98) 0.01
Family history
No Reference
Yes 2.85 (1.16–6.99) 0.03
BMI 1.15 (1.02–1.39) 0.04
Bleeding volume
Low Reference
Moderate 2.08 (0.95–5.88) 0.35
high 5.89 (2.74–9.89) 0.002
BMI: Body mass index.
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0.1 ng/mL physiologic level of 1, 25(OH) D3 inhibited 
the growth of myometrial and leiomyoma cells nearly 
12%. The inhibition of growth was dependent on 
concentration in both myometrial and leiomyoma cells. 
In both types of cells, the highest concentration of 
1,25(OH)2D3 (100 ng/mL) inhibited growth of 62% after 
rising doses of 1, 25(OH)2D3 for 9 days [26]. In another 
study by Sharan et al., Vitamin D3 suppressed fibroid 
cell growth at 1 ng/mL by 47 ± 0.03% and at 0.1 ng/mL 
by 38 ± 0.02% compared to control cells at 120 h [27]. 
The findings of aforementioned studies approved 
that 1,25(OH)2D3 was able to suppress the growth of 
myometrial and leiomyoma at a concentration of 0.1 
ng/mL within the physiological range of concentration 
(48–156 ng/mL) of 1,25(OH)2D3.
The precise molecular mechanism of 
1,25(OH)2D3 on uterine leiomyoma remains unknown, 
although degradation of extracellular matrix (ECM) is 
one of the most proposed mechanism [28]. The ECM 
is a non-cellular component three-dimensional network 
of extracellular macromolecules, such as collagen, 
enzymes, fibronectin, laminins, proteoglycans, and 
glycoproteins which present within all tissues and provide 
structural and biochemical support of surrounding 
cells [29]. Creation of UFs is stimulated by increasing 
cell proliferation and ECM deposition. The growth of 
UFs is due to the increased proliferation of cells and the 
ECMs deposition. Abnormal deposition of ECM plays a 
crucial role in the pathophysiology of UFs [30].
Vitamin D3, by increasing the expression and 
activity of metalloproteins (MMP-2 and MMP-9) involved 
in ECM degradation, inhibits the growth of UFs [31], in 
addition, by reducing the activity of transforming the 
growth factor beta 3, increased fibronectin expression, 
collagen type 1, plasminogen activator inhibitor-1 
proteins, and Smad2 phosphorylation, as well as 
Smad2 and Smad3 nuclear translocation [32].
Although Vitamin D deficiency is obviously due 
to geographical and cultural conditions, it could be also 
because of some factors associated to lifestyle, such as 
poor nutrition. This issue has not received much attention 
in national prevention and treatment programs. On the 
other hand, UFs are the most common cause of women 
being hospitalized and hysterectomy is causing high 
costs of treatment to the Ministry of Health. It should 
be taken into consideration, Vitamin D supplements, 
such as iron supplements, are compulsorily distributed 
in girls’ schools and avoid expensive medical expenses 
at low cost.
Interestingly, the duration of sunlight exposure 
was found to be significantly lower in women with UF. 
Furthermore, the frequency and volume of UF was 
found to be significantly higher in these women than 
in the control subjects; this is in agreement with prior 
reports and confirms negative correlation between 
serum Vitamin D levels and UF prevalence and volume. 
Furthermore, there was a dose dependent between 
serum Vitamin D and magnitude of fibroid tumor [33].
As with any research, this study has several 
limitations that should be acknowledge. First was 
the nature of cross-sectional design and temporality 
between Vitamin D and UF. Hence, we cannot 
infer causal inference. Another issue is the lack of 
adjustment for potential confounders. Confounding is 
the most important challenge in observational studies. 
There may be several factors like other gynecological 
diseases that can confound the association between 
Vitamin D and UF which more studies are needed to 
seek the causal association between Vitamin D and UF.
Conclusion
For women with UFs, the serum level of 
25-hydroxyvitamin D3 was significantly lower than in 
controls. Vitamin D3 deficiency is a potential risk factor 
for UFs to occur.
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